The Emerging Roles of CEACAM6 in Human Cancer (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2024 Jan 19

PMID 38240103

Authors

Guanhua Wu

Da Wang

Fei Xiong

Qi Wang

Wenzheng Liu

Junsheng Chen

Yongjun Chen

Affiliations

Soon will be listed here.

Abstract

Carcinoembryonic antigen (CEA)‑related cell adhesion molecule 6 (CEACAM6) is a cell adhesion protein of the CEA family of glycosyl phosphatidyl inositol anchored cell surface glycoproteins. A wealth of research has demonstrated that CEACAM6 is generally upregulated in pancreatic adenocarcinoma, breast cancer, non‑small cell lung cancer, gastric cancer, colon cancer and other cancers and promotes tumor progression, invasion and metastasis. The transcriptional expression of CEACAM6 is regulated by various factors, including the CD151/TGF‑β1/Smad3 axis, microRNA (miR)‑146, miR‑26a, miR‑29a/b/c, miR‑128, miR‑1256 and DNA methylation. In addition, the N‑glycosylation of CEACAM6 protein at Asn256 is mediated by α‑1,6‑mannosylglycoptotein 6‑β‑N‑acetylglucosaminyltransferase. In terms of downstream signaling pathways, CEACAM6 promotes tumor proliferation by increasing levels of cyclin D1 and cyclin‑dependent kinase 4 proteins. CEACAM6 can activate the ERK1/2/MAPK or SRC/focal adhesion kinase/PI3K/AKT pathways directly or through EGFR, leading to stimulation of tumor proliferation, invasion, migration, resistance to anoikis and chemotherapy, as well as angiogenesis. This article provides a review of the expression pattern, biological function and relationship with prognosis of CEACAM6 in cancer. In summary, CEACAM6 may be a valuable diagnostic biomarker and potential therapeutic target for human cancers exhibiting overexpression of CEACAM6.

Citing Articles

Distinct gene signatures define the epithelial cell features of mucinous appendiceal neoplasms and pseudomyxoma metastases.

Ayala C, Sathe A, Bai X, Grimes S, Shen J, Poultsides G Front Genet. 2025; 16:1536982.

PMID: 40018643 PMC: 11865047. DOI: 10.3389/fgene.2025.1536982.

Single-cell Analysis Highlights Anti-apoptotic Subpopulation Promoting Malignant Progression and Predicting Prognosis in Bladder Cancer.

Chen L, Hao Y, Zhai T, Yang F, Chen S, Lin X Cancer Inform. 2025; 24:11769351251323569.

PMID: 40018511 PMC: 11866393. DOI: 10.1177/11769351251323569.

The Importance of Genetic Screening on the Syndromes of Colorectal Cancer and Gastric Cancer: A 2024 Update.

Lupan I, Silaghi C, Stroe C, Muntean A, Deleanu D, Bintintan V Biomedicines. 2025; 12(12.

PMID: 39767561 PMC: 11674014. DOI: 10.3390/biomedicines12122655.

miR-141-3p inhibited BPA-induced proliferation and migration of lung cancer cells through PTGER4.

Ling F, Xie W, Kui X, Cai Y, He M, Ma J Cytotechnology. 2025; 77(1):28.

PMID: 39741890 PMC: 11683044. DOI: 10.1007/s10616-024-00692-5.

The influence of hypoxia-mediated CEACAM6 upregulation on epithelial cell and macrophage response in the context of gastric cancer.

Poirah I, Chakraborty D, Dixit P, Samal S, Banerjee S, Mukherjee T Eur J Clin Invest. 2024; 54 Suppl 2:e14352.

PMID: 39674878 PMC: 11646287. DOI: 10.1111/eci.14352.

References

Schettini F, Barbao P, Braso-Maristany F, Galvan P, Martinez D, Pare L . Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. ESMO Open. 2021; 6(3):100102. PMC: 8038941. DOI: 10.1016/j.esmoop.2021.100102. View

Deng X, Liu P, Zhao Y, Wang Q . Expression profiling of CEACAM6 associated with the tumorigenesis and progression in gastric adenocarcinoma. Genet Mol Res. 2014; 13(3):7686-97. DOI: 10.4238/2014.September.26.6. View

Cheng T, Chang W, Chu H, De Luca R, Pedersen J, Incerpi S . Nano-Strategies Targeting the Integrin αvβ3 Network for Cancer Therapy. Cells. 2021; 10(7). PMC: 8307885. DOI: 10.3390/cells10071684. View

Duxbury M, Ito H, Ashley S, Whang E . CEACAM6 as a novel target for indirect type 1 immunotoxin-based therapy in pancreatic adenocarcinoma. Biochem Biophys Res Commun. 2004; 317(3):837-43. DOI: 10.1016/j.bbrc.2004.03.128. View

Niu G, Murad Y, Gao H, Hu S, Guo N, Jacobson O . Molecular targeting of CEACAM6 using antibody probes of different sizes. J Control Release. 2012; 161(1):18-24. PMC: 3378815. DOI: 10.1016/j.jconrel.2012.04.043. View

Park W, Chawla A, OReilly E . Pancreatic Cancer: A Review. JAMA. 2021; 326(9):851-862. PMC: 9363152. DOI: 10.1001/jama.2021.13027. View

Zou J, Chen S, Li Y, Zeng L, Lian G, Li J . Nanoparticles modified by triple single chain antibodies for MRI examination and targeted therapy in pancreatic cancer. Nanoscale. 2020; 12(7):4473-4490. DOI: 10.1039/c9nr04976b. View

Duxbury M, Ito H, Ashley S, Whang E . c-Src-dependent cross-talk between CEACAM6 and alphavbeta3 integrin enhances pancreatic adenocarcinoma cell adhesion to extracellular matrix components. Biochem Biophys Res Commun. 2004; 317(1):133-41. DOI: 10.1016/j.bbrc.2004.03.018. View

Chen J, Li Q, An Y, Lv N, Xue X, Wei J . CEACAM6 induces epithelial-mesenchymal transition and mediates invasion and metastasis in pancreatic cancer. Int J Oncol. 2013; 43(3):877-85. DOI: 10.3892/ijo.2013.2015. View

10.

Skubitz K, Campbell K, Skubitz A . CD66a, CD66b, CD66c, and CD66d each independently stimulate neutrophils. J Leukoc Biol. 1996; 60(1):106-17. DOI: 10.1002/jlb.60.1.106. View

11.

Wu S, Arundhathi A, Wang H, Chen C, Cheng T, Yuan S . Migration and invasion of NSCLC suppressed by the downregulation of Src/focal adhesion kinase using single, double and tetra domain anti- CEACAM6 antibodies. Transl Oncol. 2021; 14(7):101057. PMC: 8105299. DOI: 10.1016/j.tranon.2021.101057. View

12.

Frangsmyr L, Baranov V, Hammarstrom S . Four carcinoembryonic antigen subfamily members, CEA, NCA, BGP and CGM2, selectively expressed in the normal human colonic epithelium, are integral components of the fuzzy coat. Tumour Biol. 1999; 20(5):277-92. DOI: 10.1159/000030075. View

13.

Tian C, Zhang B, Ge C . Effect of silencing on the biological behavior of human gallbladder cancer cells. Oncol Lett. 2020; 20(3):2677-2688. PMC: 7400980. DOI: 10.3892/ol.2020.11806. View

14.

Son S, Yun J, Lee S, Han H, Lim Y, Woo C . Therapeutic Effect of pHLIP-mediated CEACAM6 Gene Silencing in Lung Adenocarcinoma. Sci Rep. 2019; 9(1):11607. PMC: 6717735. DOI: 10.1038/s41598-019-48104-5. View

15.

Chen S, Zhang R, Duan G . Pathogenic mechanisms of the oncoprotein CagA in H. pylori-induced gastric cancer (Review). Oncol Rep. 2016; 36(6):3087-3094. DOI: 10.3892/or.2016.5145. View

16.

Wautier J, Wautier M . Old and New Blood Markers in Human Colorectal Cancer. Int J Mol Sci. 2022; 23(21). PMC: 9656373. DOI: 10.3390/ijms232112968. View

17.

Duxbury M, Ito H, Benoit E, Zinner M, Ashley S, Whang E . Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. Oncogene. 2004; 23(34):5834-42. DOI: 10.1038/sj.onc.1207775. View

18.

Pandey R, Zhou M, Islam S, Chen B, Barker N, Langlais P . Carcinoembryonic antigen cell adhesion molecule 6 (CEACAM6) in Pancreatic Ductal Adenocarcinoma (PDA): An integrative analysis of a novel therapeutic target. Sci Rep. 2019; 9(1):18347. PMC: 6893022. DOI: 10.1038/s41598-019-54545-9. View

19.

Zid M, Drouin G . Gene conversions are under purifying selection in the carcinoembryonic antigen immunoglobulin gene families of primates. Genomics. 2013; 102(4):301-9. DOI: 10.1016/j.ygeno.2013.07.003. View

20.

Witzens-Harig M, Hose D, Junger S, Pfirschke C, Khandelwal N, Umansky L . Tumor cells in multiple myeloma patients inhibit myeloma-reactive T cells through carcinoembryonic antigen-related cell adhesion molecule-6. Blood. 2013; 121(22):4493-503. DOI: 10.1182/blood-2012-05-429415. View